As a business, Purisys has a history of working with the development of APIs that stretches back 40 years. As a former business of Johnson & Johnson, we began manufacturing codeine phosphate in 1979. In the 1980s, Johnson & Johnson became more involved with controlled substance manufacturing, formerly entering the trade API pain management market in 1986.
At the turn of the 21st Century, J&J’s Athens, GA facility – now home base for Purisys manufacturing and R&D – was inaugurated for the manufacture of high potency APIs. This business became a global leader in pain management finished products and high quality intermediates over the next 15 years.
In 2016, this business was purchased by SK Capital, retaining the name Noramco. In 2019, Purisys was spun off from Noramco to capitalize and focus on its strengths in clinical API development and manufacturing, synthetically manufactured cannabinoids and finished products.